NCT03671590 2024-07-19Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTG Therapeutics, Inc.Phase 1 Terminated172 enrolled
NCT02006485 2019-11-05Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesTG Therapeutics, Inc.Phase 1 Completed160 enrolled